Tropisetron citrate

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H20N2O2.C6H8O7
Molecular Weight	476.4764
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C3=CNC4=C3C=CC=C4

InChI

InChIKey=YFGSHODXSPKSDQ-LUNMCBQDSA-N

InChI=1S/C17H20N2O2.C6H8O7/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16;7-3(8)1-6(13,5(11)12)2-4(9)10/h2-5,10-13,18H,6-9H2,1H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,12+,13+;

HIDE SMILES / InChI

Molecular Formula	C6H8O7
Molecular Weight	192.1235
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C17H20N2O2
Molecular Weight	284.3529
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.medsafe.govt.nz/profs/Datasheet/t/tropisetronaftinj.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7507039

Tropisetron (Tropisetron-AFT) is a potent and selective serotonin 3 (5-hydroxytryptamine3; 5-HT3) receptor antagonist with antiemetic properties, probably mediated via antagonism of receptors both at peripheral sites and in the central nervous system. Surgery and treatment with certain substances, including some chemotherapeutic agents, may trigger the release of serotonin from enterochromaffin-like cells in the visceral mucosa and initiate the emesis reflex and its accompanying feeling of nausea. Tropisetron (Tropisetron-AFT) selectively blocks the excitation of the presynaptic 5-HT3 receptors of the peripheral neurons in this reflex, and may exert additional direct actions within the CNS on 5-HT3 receptors mediating the actions of vagal input to the area postrema.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 3a (5-HT3a) receptor 48 Target ID: CHEMBL1899 Sources: http://www.medsafe.govt.nz/profs/Datasheet/t/tropisetronaftinj.pdf	Antagonist 2849		8.48 null [pKi]

Conditions

Condition	Modality	Highest Phase	Product
Postoperative nausea and vomiting 31 Sources: http://www.medsafe.govt.nz/profs/Datasheet/t/tropisetronaftinj.pdf	Curative	Approved 8583	Tropisetron-AFT Approved Use For the prevention of nausea and vomiting induced by cytotoxic therapy (5 mg/5 mL ampoule only). For the treatment and prevention of post-operative nausea and vomiting in adults (2 mg/2 mL ampoule only). Launch Date 2012
Nausea induced by cytotoxic therapy 3 Sources: http://www.medsafe.govt.nz/profs/Datasheet/t/tropisetronaftinj.pdf	Preventing	Approved 8583	Tropisetron-AFT Approved Use For the prevention of nausea and vomiting induced by cytotoxic therapy (5 mg/5 mL ampoule only). For the treatment and prevention of post-operative nausea and vomiting in adults (2 mg/2 mL ampoule only). Launch Date 2012
Vomiting induced by cytotoxic therapy 3 Sources: http://www.medsafe.govt.nz/profs/Datasheet/t/tropisetronaftinj.pdf	Preventing	Approved 8583	Tropisetron-AFT Approved Use For the prevention of nausea and vomiting induced by cytotoxic therapy (5 mg/5 mL ampoule only). For the treatment and prevention of post-operative nausea and vomiting in adults (2 mg/2 mL ampoule only). Launch Date 2012

C_max

Value	Dose	Analyte	Population
15.1 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/11736884/	2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.46 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/11736884/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
84 mg/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
76 mg/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
150 mg/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
211 mg/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
82 mg/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
20.7 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/11736884/	2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
32.9 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/11736884/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
239 mg × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
195 mg × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
410 mg × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
450 mg × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1192 mg × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
5.6 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/11736884/	2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.7 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/11736884/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.3 h REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
6.7 h REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
13.5 h REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12.1 h REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
30.3 h REVIEW https://pubmed.ncbi.nlm.nih.gov/8363993/ \| https://www.sciencedirect.com/science/article/pii/S0923753419650428/pdf?md5=053694846466cf9e1daea50a7812ae48&pid=1-s2.0-S0923753419650428-main.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TROPISETRON plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
41% REVIEW https://pubmed.ncbi.nlm.nih.gov/30672837/			TROPISETRON plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
15 mg 1 times / day multiple, oral Highest studied dose Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/	Disc. AE: Nausea, Hypoglycemia... AEs leading to discontinuation/dose reduction: Nausea (2.4%) Hypoglycemia (2.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/
50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/	Disc. AE: Constipation, Skin reaction... AEs leading to discontinuation/dose reduction: Constipation (4%) Skin reaction (4%) Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/	Disc. AE: Fever, Macular rash... AEs leading to discontinuation/dose reduction: Fever Macular rash Hypotension (grade 1) Joint aches Lymphadenopathy cervical Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/

AEs

AE	Significance	Dose	Population
Hypoglycemia	2.4% Disc. AE	15 mg 1 times / day multiple, oral Highest studied dose Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/
Nausea	2.4% Disc. AE	15 mg 1 times / day multiple, oral Highest studied dose Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/
Constipation	4% Disc. AE	50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/
Skin reaction	4% Disc. AE	50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/1876437/
Fever	Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/
Joint aches	Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/
Lymphadenopathy cervical	Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/
Macular rash	Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/
Hypotension	grade 1 Disc. AE	20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2885485/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507 substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2E1 1060 CYP2A6 879 CYP2C19 2057 CYP1A2 2153 CYP19A1 429 OCT2 779 Nav1.5 116 MATE1 415 OCT1 620	CYP2E 3 P-gp 2052 CYP3A 220 CYP1A 26 CYP2C 16

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNTY1NjQifX0=	inconclusive [IC50 0.5012 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNTY1NjQifX0=	inconclusive [IC50 31.6228 uM]
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/34208557/	moderate [IC50 31.3 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU2NTY0In19	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU2NTY0In19	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU2NTY0In19	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU2NTY0In19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDU2NTY0In19	no [IC50 >10 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/656665#section=Biological-Test-Results Page: 220.0	no
MATE1 416	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/34208557/	yes [IC50 1.6 uM]
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/20921968/	yes [IC50 8.5 uM]	yes (pharmacogenomic study) Comment: Patients with two loss-of-function OCT1 alleles had higher tropisetron plasma concentrations (n ¼ 59, Po0.04) and higher clinical efficacy (n ¼ 91, P ¼ 0.009) compared with carriers of fully active OCT1. Sources: https://pubmed.ncbi.nlm.nih.gov/20921968/

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/656665#section=Biological-Test-Results Page: 37 \| 256	inconclusive
CYP1A 26	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/8013282/	likely
CYP2C 16	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/8013282/	likely
CYP2E 3	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/8013282/	likely
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/8013282/ \| https://pubmed.ncbi.nlm.nih.gov/12065557/	major	yes (pharmacogenomic study) Comment: Genetically defined poor metabolizers had higher serum concentrations of tropisetron than all other patients (P <.03). Sources: https://pubmed.ncbi.nlm.nih.gov/8013282/ \| https://pubmed.ncbi.nlm.nih.gov/12065557/
CYP3A 220	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/8013282/	minor

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
Nav1.5 119	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/27401036/
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNTY1NjQifX0=

PubMed

Title	Date	PubMed
A comparative study of prophylactic antiemetic treatment in cancer patients receiving radiotherapy.	2010-04-24	20414924
[Impact of intrathecal morphine on the tolerance of early feeding after cesarean section].	2010-02	20117912
Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines.	2010	20034341
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy.	2009-12-10	21188135
Liquid chromatography/tandem mass spectrometry method for the quantification of deserpidine in human plasma: Application to a pharmacokinetic study.	2009-10-01	19620026
Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron.	2009-08-10	21188127
[Nicotinic acetylcholine receptors are possible therapeutic targets for schizophrenia].	2009-02	19182447
The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew.	2009-01	18727934
[Therapeutic effect of acupuncture on cisplatin-induced nausea and vomiting].	2009-01	19186712
Fibromyalgia: diagnosis and treatment options.	2009	19406366
New treatment options in the management of fibromyalgia: role of pregabalin.	2008-12	19337459
Serotonin mediates PGE2 overexpression through 5-HT2A and 5-HT3 receptor subtypes in serum-free tissue culture of macrophage-like synovial cells.	2008-08	18368410
Chemotherapy-and cancer-related nausea and vomiting.	2008-01	18231647
[Prophylactic effect of tropisetron hydrochloride against nausea and vomiting in patients receiving chemotherapy for hematological malignancies].	2007-09	17876159
Translating pharmacogenomics: challenges on the road to the clinic.	2007-08	17696640
Postoperative colonic motility after tropisetron and a standardized meal in patients undergoing conventional colorectal surgery.	2007-05	16941175
Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy.	2007-04	17093916
5-HT acts on nociceptive primary afferents through an indirect mechanism to induce hyperalgesia in the subcutaneous tissue.	2007-03-16	17257768
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction.	2007-02-21	17309673
A randomized, placebo-controlled trial of a single dose of tropisetron for the prevention of vomiting after strabismus surgery in children.	2006-12	17285204
[5-HT3 receptor antagonist als analgetics in rheumatic diseases].	2006-10	16450149
Increased 5-HT(3)-mediated signalling in pelvic afferent neurons from mice deficient in P2X(2) and/or P2X (3) receptor subunits.	2006-09	18404485
Luminal hypotonicity increases duodenal mucosal permeability by a mechanism involving 5-hydroxytryptamine.	2006-01	16497179
New treatment options using 5-HT3 receptor antagonists in rheumatic diseases.	2006	17017973
Tropisetron improves deficits in auditory P50 suppression in schizophrenia.	2005-07-01	15927799
Stimulation of the lateral hypothalamus produces antinociception mediated by 5-HT1A, 5-HT1B and 5-HT3 receptors in the rat spinal cord dorsal horn.	2005	16165284
Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?	2005	15740177
Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids.	2004-08-02	15266329
Cloning, pharmacological characterisation and tissue distribution of a novel 5-HT4 receptor splice variant, 5-HT4(i).	2004-06	15118808
The assessment of vegetative and functional symptoms in fibromyalgia patients: the tropisetron experience.	2004	15515419
Intravenous treatment of fibromyalgia with the 5-HT3 receptor antagonist tropisetron in a rheumatological practice.	2004	15515420
The influence of the 5-HT3 receptor antagonist tropisetron on pain in fibromyalgia: a functional magnetic resonance imaging pilot study.	2004	15515408
Participation of the serotonin system in rofecoxib-induced antinociception.	2004	15633624
[What's new in the therapy of fibromyalgia?].	2003-12	14648317
Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects.	2003-06	12728290
[5-HT3-receptor-antagonists in therapy of rheumatic diseases].	2003-02	12624802
Plasma serotonin and histamine levels in hemodialysis-related pruritus are not significantly influenced by 5-HT3 receptor blocker and antihistaminic therapy.	2003-02	12608555
Effects of serotonin-3 receptor antagonists on the intracranial self-administration of ethanol within the ventral tegmental area of Wistar rats.	2003-01	12447605
Further evidence that the discriminative stimulus properties of indorenate are mediated by 5-HT 1A/1B/2C receptors.	2003-01	12479957
Low-dose dexamethasone reduces nausea and vomiting after tympanomastoid surgery: a comparison of tropisetron with saline.	2002-09-20	12239690
Small-dose dexamethasone reduces nausea and vomiting after laparoscopic cholecystectomy: a comparison of tropisetron with saline.	2002-07	12088975
[Pharmacoeconomical model for cost calculation using a study on prophylaxis of nausea and vomiting in the postoperative phase as an example. Cost effectiveness analysis of a tropisetron supplemented desflurane anaesthesia in comparison to a propofol total intravenous anaesthesia (TIVA)].	2002-06	12391535
5-HT(4) receptor antagonists: structure-affinity relationships and ligand-receptor interactions.	2002-06	12052197
Simultaneous determination of ondansetron and tropisetron in human plasma using HPLC with UV detection.	2002-05	11920943
[Pilot study with 5-HT3 antagonists. Good outcome in fibromyalgia pain].	2002-03-14	12066514
The prophylactic effect of tropisetron on epidural morphine-related nausea and vomiting: a comparison of dexamethasone with saline.	2002-03	11867410
Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen.	2002-01-21	11870508
Inhibition of ganglionic long-term potentiation decreases blood pressure in spontaneously hypertensive rats.	2001-12	11743138
Relaxation induced by serotonin and sumatriptan in isolated guinea pig gallbladder strips.	2001-03	11426669
[3H]5-hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT4 receptor.	1996-05-23	8813606

Patents

Sample Use Guides

In Vivo Use Guide

Prevention of nausea and vomiting induced by cytotoxic therapy: Tropisetron-AFT is recommended as six-day courses of 5 mg per day, given intravenously on day 1 immediately before cancer chemotherapy followed by oral administration on days 2 to 6. Treatment and prevention of post-operative nausea and vomiting: Tropisetron-AFT is recommended as a 2 mg dose given intravenously. For the prevention of post- operative nausea and vomiting, tropisetron should be administered shortly before the induction of anaesthesia.

Route of Administration: Intravenous

In Vitro Use Guide

The effects of tropisetron on 5-HT3 receptors were examined in N1E-115 mouse neuroblastoma x rat glioma hybrid cells. The 5HT3 receptor ligand [3H] quipazine was displaced by tropisetron with Ki value of 2.25 nM. IC50 value for inhibition of 5HT-induced inward current by tropisetron was 0.22 nM at a holding potential of -65 mV.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 16:29:39 GMT 2025` Edited by `admin` on `Wed Apr 02 16:29:39 GMT 2025`
Record UNII	TAX4GZ9E39
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Tropisetron citrate [WHO-DD]

Preferred Name

English

Tropisetron citrate

Common Name

English

1H-Indole-3-carboxylic acid, (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

Systematic Name

English

Code System Code Type Description

SMS_ID

300000037348

Created by admin on Wed Apr 02 16:29:39 GMT 2025 , Edited by admin on Wed Apr 02 16:29:39 GMT 2025

PRIMARY

FDA UNII

TAX4GZ9E39

Created by admin on Wed Apr 02 16:29:39 GMT 2025 , Edited by admin on Wed Apr 02 16:29:39 GMT 2025

PRIMARY

CAS

1251773-00-8

Created by admin on Wed Apr 02 16:29:39 GMT 2025 , Edited by admin on Wed Apr 02 16:29:39 GMT 2025

PRIMARY

Related Record Type Details


					6I819NIK1W

TROPISETRON

PARENT -> SALT/SOLVATE

Amount:


					XF417D3PSL

Anhydrous citric acid

PARENT -> SALT/SOLVATE

Amount:

Details

SMILES

InChI

DescriptionSources: http://www.medsafe.govt.nz/profs/Datasheet/t/tropisetronaftinj.pdfCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7507039

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.medsafe.govt.nz/profs/Datasheet/t/tropisetronaftinj.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7507039

C_max

T_1/2

F_unbound

Drug as perpetrator